OncoHost - Together

Led by an experienced team of entrepreneurs, industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost aims to understand the patient's unique response to therapy to overcome one of the maior obstacles in clinical oncology today - resistance to treatment. Supported by robust clinical evidence, strong IP positioning, and first -mover advantage, OncoHost has developed the PROphet® platform. Combining bioinformatics, system biology and machine learning PROphet provides insights to aid the best choice for therapy.

Type Stocks

Category Bio-Tech

Minimum Investment 20,000$

A simple blood test that helps tailor treatment plans for cancer patients

Immunotherapy, which harnesses the patient’s own immune system to attack cancer cells, has recently emerged as one of the most promising treatments for cancer. While it can be a life-saving treatment for some, most do not respond, and there is risk for immune-related complications. Therefore, doctors need tools to predict whether their patients will respond to therapy, and to tailor treatment plans accordingly.

OncoHost, an Israeli start-up company, is developing breakthrough technology for a personalized approach to cancer management. Using machine-learning algorithms to analyze large datasets of blood proteins, OncoHost has developed PROphet®, a simple blood test that accurately predicts response to cancer immunotherapies and identifies potential strategies to overcome resistance to treatment. PROphet® aids the doctor in choosing the right therapy for the individual patient, increasing the chances that the therapy will be successful and limiting unnecessary complications.

Huge Savings for Healthcare Systems

The immunotherapy market is growing rapidly, and its worth is currently estimated at around 30 billion dollars. OncoHost will revolutionize the market with its patented PROphet^® blood test.

OncoHost’s solution will not only saves lives, but will also save billions of dollars for healthcare systems worldwide. Some immunotherapy treatments cost as much as 100 thousand dollars for a single patient. Therefore, knowing beforehand or very early on during treatment whether the patient will benefit from these expensive treatments is extremely valuable for healthcare systems and insurers. PROphet® will aid in restricting costly therapies to patients who are most likely to benefit from them, offering a cost-effective and sustainable approach to cancer management.

Join the investment in OncoHost >>

How Does it Work?

Two blood samples are drawn from the patient, one before treatment and one two weeks after treatment has commenced.
The samples are scanned by OncoHost’s unique method, which analyzes over 400 proteins.
Patterns related to response or resistance to therapy are identified.
A report is provided to the doctor and patient.
Doctor and patient make informed decisions about next lines of treatment.

PROphet^® translates the protein profiles in the blood into information that helps identify the most suitable treatment plans for the individual patient. Within two weeks of the first treatment dose, PROphet^® can determine the probability of a patient responding to the therapy. If the probability of response is low, PROphet® identifies other treatments that might be suitable for the patient.

Join the investment in OncoHost >>

The Company’s Advantages:

Offers an innovative platform unlike any other.
Operates in a growing market.
Saves on tremendous costs to healthcare systems and insurance companies.
Proven technology, expected to launch in 2021.
Can save lives by tailoring treatment plans.
Offers a simple, convenient and non-invasive test

Join the investment in OncoHost >>

Encouraged by Health Organizations

Health organizations around the globe understand the heavy financial burden and expected mortality from cancer in the near future. It’s predicted that 1.3 million people will likely die from cancer in the year 2020 in Europe alone. Hence, identifying the right therapy for every patient is of highest priority.

The OncoHost platform will maximize clinical benefit, minimize complications from unnecessary treatments and reduce financial burden.

Join the investment in OncoHost >>

OncoHost, founded in 2017, is a biotechnology start-up company developing breakthrough innovations, addressing the greatest unmet needs in clinical oncology today

The Company’s basic assumption is that not all patients respond alike to treatment – while it may be effective for some, others may not be affected at all, and other patients may be harmed by the treatment. The blood test developed by OncoHost can decipher after two weeks of the first treatment dose whether it’s suitable for the patient’s body or not.

In contrast with the prevalent approach today, where all patients receive the same immunotherapy treatment according to general data, the OncoHost patented PROphet® test specifically examines the effect of treatment on the patient’s body.

Therefore, helping to prevent the unnecessary heavy expenditure by healthcare systems, but more importantly, it can help change the treatment strategy and save lives.

OncoHost is led by an exceptional management team comprised of world-renowned oncologists, scientists and healthcare executives.

Dr. Ofer Sharon - CEO

Physician and entrepreneur, Dr. Sharon has nearly 20 years of experience in clinical and commercial product development for startup companies in the health, biotech and medical device industries. Prior to joining OncoHost, he held several positions in global pharmaceutical companies, and co-founded several medical companies, focusing mainly on bioinformatics and machine learning technologies.
Dr. Sharon received his MD cum laude from the Tel Aviv University in Israel.

Prof. Yuval Shaked - PhD, Founder and Chief Scientific Advisor

Prof. Shaked leads an academic research laboratory at the Faculty of Medicine at the Technion – Israel Institute of Technology. His pioneering research focuses on understanding tumor-host interactions and mechanisms of tumor progression, which is the scientific basis for OncoHost’s technology.
Prof. Shaked is currently head of the Technion Integrated Cancer Center and President of the International Cancer Microenvironment Society. He formerly served as Vice Dean of Research at the Rappaport Faculty of Medicine at the Technion. Prof. Shaked is also a member of several cancer societies, including the American Association for Cancer Research (AACR), the European Association of Cancer Research (EACR) and the Israel Society of Cancer Research (ISCR). Prof. Shaked is author and co-author of over 100 scientific publications and five patents.

Prof. Adam Dicker - MD, PhD, Chief Medical Officer

Prof. Adam Dicker is a leading radiation oncologist, serving as Senior Vice President and Chair at the Jefferson Institute for Digital Health. For his significant contribution to oncological research, education and patient care, Prof. Dicker was named Fellow of the American Society of Clinical Oncology (ASCO) and named Fellow of the American Society for Radiation Oncology (ASTRO).
Prof. Dicker is the former Chair of the AACR Radiation Oncology Section of the Clinical Research Subcommittee; Chair of the ASCO-ASTRO Radiation Oncology Panel; Co-chair of NRG Oncology’s Translational Science and Digital Health committees; Co-Chair of the NCI Radiation Oncology Working Group; Editorial board member for several scientific journals.

Dr. Galit Yahalom - PhD, VP Clinical and Regulatory Affairs

Dr. Yahalom has over 15 years of experience in the biotech industry, with a proven record in end-to-end diagnostic product development, including R&D, clinical studies, and regulatory submissions. She was also co-founder of several biomedical diagnostic companies. Dr. Yahalom holds a PhD in molecular biology from the Weizmann Institute of Science.

PhD, Bioinformatics Scientist - Dr. Michal Harel

Dr. Harel has over 8 years of experience in OMIC-level bioinformatics analysis, specializing in proteomics data. Prior to joining OncoHost, Dr. Harel worked as a research associate at Tel Aviv University. She received her PhD from the Weizmann Institute of Science, and was a postdoctoral fellow at the Technion – Israel Institute of Technology.